<DOC>
	<DOC>NCT00439959</DOC>
	<brief_summary>This study represents the first administration of GSK625433 in humans. The study is designed to evaluate initial safety and tolerability in healthy adults as well as anti-viral activity in Hepatitis C(HVC) infected adults. The way the human body processes GSK625433 will also be investigated.</brief_summary>
	<brief_title>Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Inclusion criteria: Healthy males &amp; females Part 1 ages 1860 Part 2 ages 1850 &amp; 6580 Within normal weight range given your height Negative urine drug and alcohol test Willing to follow all study procedures Exclusion criteria: Any significant abnormal lab, ECG, medical or physical exam finding during screening Allergy to the study drug Excessive alcohol intake Positive HIV or hepatitis B or C result Use of prescription or nonprescription drugs within one week of study start except for birth control Blood pressure meds &amp; Tylenol Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>GSK625433,</keyword>
	<keyword>Hepatitis C,</keyword>
	<keyword>metabolic probe,</keyword>
	<keyword>food-effect,</keyword>
	<keyword>HCV,</keyword>
	<keyword>FTIH</keyword>
	<keyword>polymerase,</keyword>
</DOC>